Sunday, July 29, 2012

Fredrik T Week 6 (reupload)


After all involved legal departments finally approved the clinical trial the first patient could come in for his injections this week. The clinical trial aims to develop a method for guided prostate biopsy using a Prostate Specific Membrane Antigen (PSMA) specific antibody (J591) conjugated to a radioactive Zr89 nucleus. The standard of care is to blindly take out between 10 and 15 biopsies of the prostate when there is reason to believe that the patient might have neoplastic lesions, e.g. after the patient has tested with an elevated PSA level. A guided biopsy would decrease the risk of a lesion being missed and also allow for fewer biopsied to be made. The patients are thus injected with the J591-Zr89 conjugate, followed by PET and MRI imaging. After the prostate is removed it is imaged in a micro PET and micro MRI to be able to correlate the PET signal directly to the presence of a neoplastic lesion.

I was also trained for flow cytometry at HSS in preparation for the TGF-beta transition experiments in the Bander Lab.

I also finally had my meeting with Dr Vahdat to discuss the use of our GEDI chip to capture progenitor cells from breast cancer patient blood samples. It was decided that initially primary HUVECs will be used for capture in lieu of blood samples. 

No comments:

Post a Comment